Ulcerative Colitis Clinical Trials

22 trials recruiting in Canada.

Digestive Health

Recruiting Drug Device Behavioral Older adults Healthy volunteers

18 trials

Testing Afimkibart for moderately to severely active ulcerative colitis

Explore this study →

One site, in Toronto

Official title: A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis

Moderately to Severely Active Ulcerative Colitis · Hoffmann-La Roche

Comparing LY4268989 with Mirikizumab for ulcerative colitis

Explore this study →

Sites in London, Hamilton and 2 more cities

RecruitingPHASE2

Official title: LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

Ulcerative Colitis · Eli Lilly and Company

Testing LY4268989 against a placebo for ulcerative colitis (UC)

Explore this study →

Sites in Greater Sudbury, Halifax and 1 more city

RecruitingPHASE2

Official title: LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis (UC) · Eli Lilly and Company

Get matched to the best-fit trials

Answer a few questions and we'll find the closest matches for ulcerative colitis.

Comparing 7 approaches for ulcerative colitis

Explore this study →

Sites in London and Toronto

RecruitingPHASE3

Official title: A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

Ulcerative Colitis · Eli Lilly and Company

Testing Lyophilized fecal microbiota against a placebo for ulcerative colitis

Explore this study →

One site, in Edmonton

RecruitingPHASE2

Official title: LFMT vs Placebo in New Biologic Start for Ulcerative Colitis

Ulcerative Colitis · University of Alberta

Comparing 7 approaches for ulcerative colitis

Explore this study →

Sites in Edmonton, London and 2 more cities

RecruitingPHASE3

Official title: A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

Ulcerative Colitis · Takeda

Testing Tilpisertib Fosmecarbil against a placebo for ulcerative colitis

Explore this study →

Sites in Toronto, London and 1 more city

RecruitingPHASE2

Official title: Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis · Gilead Sciences

Testing Vedolizumab with Tofacitinib for ulcerative colitis

Explore this study →

Sites in Barrie, London and 7 more cities

RecruitingPHASE4

Official title: A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)

Ulcerative Colitis · Takeda

Testing Afimkibart against a placebo for moderately to severely active ulcerative colitis

Explore this study →

Sites in London, Barrie and 3 more cities

RecruitingPHASE3

Official title: A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis

Moderately to Severely Active Ulcerative Colitis · Hoffmann-La Roche

Testing XmAb942 against a placebo for ulcerative colitis (UC)

Explore this study →

Sites in London, Montreal and 2 more cities

RecruitingPHASE1

Official title: Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis

Ulcerative Colitis (UC) · Xencor, Inc.

Comparing 3 approaches for ulcerative colitis (UC)

Explore this study →

2 sites in Montreal

RecruitingPHASE2

Official title: Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis (UC) · Odyssey Therapeutics

Comparing 5 approaches for ulcerative colitis

Explore this study →

Sites in Montreal and London

RecruitingPHASE2

Official title: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

Ulcerative Colitis · Genentech, Inc.

Testing SPY001 against a placebo for ulcerative colitis

Explore this study →

Sites in London, Greater Sudbury and 1 more city

RecruitingPHASE2

Official title: A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis

Ulcerative Colitis · Spyre Therapeutics, Inc.

Comparing 15 approaches for ulcerative colitis

Explore this study →

Sites in Calgary, Edmonton and 1 more city

RecruitingPHASE3

Official title: A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis

Ulcerative Colitis · AbbVie

Testing Duvakitug against a placebo for ulcerative colitis

Explore this study →

Sites in Hamilton, Oakville and 1 more city

RecruitingPHASE3

Official title: An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis · Sanofi

Testing Duvakitug against a placebo for ulcerative colitis

Explore this study →

Sites in Hamilton and Toronto

RecruitingPHASE3

Official title: A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis · Sanofi

Comparing Tirzepatide with Mirikizumab for ulcerative colitis

Explore this study →

Sites in London, Vancouver and 2 more cities

RecruitingPHASE3

Official title: Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

Ulcerative Colitis · Eli Lilly and Company

Comparing 4 approaches for ulcerative colitis

Explore this study →

Sites in London and Montreal

RecruitingPHASE2

Official title: A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis · Eli Lilly and Company

Looking for the closest fit?

Get matched →

Get notified when a matching trial opens

We'll watch for Ulcerative Colitis trials near you.

← Back to all conditions

Concord provides information support only. Trial listings come from public registries; eligibility is always determined by the trial site and your care team.